通化東寶(600867.SH)擬減資退出統博生物 應收取減資款1692.72萬元
格隆匯10月22日丨通化東寶(600867.SH)公佈,公司擬通過減資方式退出通化統博生物醫藥有限公司(以下簡稱“統博生物”),減資價格以統博生物在評估基準日2020年9月30日的淨資產評估值為基礎,乘以公司持有的統博生物股權比例確定,公司應收取的減資款為1692.72萬元。本次減資完成後,公司不再持有統博生物的股權,統博生物股東變更為東寶實業集團有限公司(以下簡稱“東寶集團”)和冷春生,持股比例分別為25%、75%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.